Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0001104659-26-012072·BioXcel Therapeutics, Inc.
Schedule 13G ownership disclosure
BIOXCEL THERAPEUTICS INC
Common Stock, par value $0.001 per share · CUSIP: 09075P204
Event date: 2025-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Integrated Core Strategies (US) LLC
Shares: 1,833,717.00 · Class: 8.4%
- Millennium Management LLC
Shares: 1,835,192.00 · Class: 8.4%
- Millennium Group Management LLC
Shares: 1,835,192.00 · Class: 8.4%
- Israel A. Englander
Shares: 1,835,192.00 · Class: 8.4%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001104659-26-012072
- Form type
- SCHEDULE 13G/A
- Filer
- BioXcel Therapeutics, Inc.
- CIK
- CIK 1720893
- Filed
- Feb 09, 2026
- Reporting period
- Dec 31, 2025
- Description
- Schedule 13G beneficial ownership